Objective To investigate into the effects of resveratrol on oxidative stress of rats with diabetic cardiomyopathy and its potential underlying mechanisms. Methods Experimental animals were divided into four groups: control mice, diabetic mice, diabetic mice treated with resveratrol, and diabetic mice treated with resveratrol and AMPK inhibitor Compound C. Expression of Drp1, p Drp1, AMPK and pAMPK was detected by Western blotting, and SOD activity and ROS were detected by the colorimetric method. Results The relative expression of p Drp1 (ser637), pAMPK and the activity of SOD were significantly decreased in diabetic cardiomyopathy as compared with the control group. ROS content was significantly increased in diabetic cardiomyopathy as compared with their counterparts. Resveratrol treatment increased the expression of pAMPK, p Drp1 (ser637), and the activity of SOD and decreased ROS content. However, the function of resveratrol was blocked by Compound C. Conclusion Resveratrol may reduce oxidative stress of diabetic cardiomyopathy through AMPK-Drp1 signaling pathway.

Objective:To formulate an evidence-based treatment plan for the aged patient with primary carcino-ma of the liver.Methods:The search strategy was determined by EBM.Based on the PICO principle,the clinical problems were put forward after full evaluation of patients'conditions.We searched the Embase(1990 -2014),Co-chrane library(Issue 9,2014),PubMed(1980 -2014),CHKD and CNKI periodical database to identify systematic reviews(SRs),randomized controlled trails(RCTs)involving the treatment for the aged patient with primary carcino-ma of the liver.All the collected evidence was critically assessed.Patient preferences was also taken into consideration in the decision-making treatment.Results:A total of 7 RCTs,4 systematic reviews/Meta-analyses were identified. A rational treatment plan was made upon a serious evaluation of the data and the opinion of the patient.After one year of follow-up,the plan was proved optimal.Conclusion:The treatment plan according to evidence-based method for the aged patient with primary carcinoma of the liver can effectively improve the therapeutic efficacy.

目的 探讨自拟益气养阴解毒汤联合GP方案化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效.方法 将98例患者随机分为对照组和观察组各49例,对照组给予GP方案(吉西他滨+顺铂)化疗,观察组给予GP方案化疗联合自拟益气养阴解毒汤治疗,对比两组疗效及安全性.结果 观察组总有效率63.27％和临床获益率89.79％均分别优于对照组的32.65％和67.35％(均P＜ 0.05).两组治疗前中医证候评分、生活质量(SF-36)、KP5评分差别不大(均P＞ 0.05).两组治疗后中医证候评分、生活质量(SF-36)、KPS评分与治疗前比较,均明显改善(均P＜ 0.05),且观察组中医证候评分、生活质量(SF-36)、KPS评分改善均优于对照组(均P＜0.05).两组治疗前CD3+、CD4+、CD8+、CD4+/CD8+、NK/％均差别不大(均P＞ 0.05).治疗后两组患者外周血CD3+、CD4+、CD8+、CD4+/CD8+、NK/％与治疗前比较,均明显上升(均P＜0.05),且观察组改善优于对照组(均P＜0.05).观察组不良反应程度评分低于对照组(P＜0.05).结论 DP方案化疗基础上给予自拟益气养阴解毒汤辅助治疗晚期NSCLC可提高疗效,减少GP方案化疗毒副作用,充分调动机体自身免疫及抑瘤机能,改善晚期NSCLC患者中医证候、生活质量、体能状况.

目的研制复方左氧氟沙星凝胶剂,制定质量控制标准.方法以卡波姆-940为主要凝胶基质,左氧氟沙星、替硝唑为主药制备凝胶剂.采用紫外分光光度法同时测定左氧氟沙星和替硝唑的含量.结果制备的凝胶剂均匀细腻,粘附性好,质量稳定,左氧氟沙星在3.0～8.0μg·ml-1范围内线性关系良好,替硝唑在12.0～32.0μg·ml-1范围内线性关系良好,左氧氟沙星和替硝唑平均回收率分别为100.15%、100.14%,RSD分别为0.84%、1.31%.结论制剂制备工艺简单,含量测定操作简便,结果准确.